Dong Wang

Company snapshot

Dong Wang is a pharma organization headquartered in CN. Primary therapeutic focus areas include Androgenetic Alopecia, Acute Myocardial Infarction, Type 2 Diabetes Mellitus, Postmenopausal Osteoporosis, Alzheimer's Disease. NovaPharmaNews links 8 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (2), approved (2), phase 3 (2).

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dong Wang. Not investment advice.

• What is Dong Wang?

  Dong Wang is a pharma organization headquartered in CN. Primary therapeutic focus areas include Androgenetic Alopecia, Acute Myocardial Infarction, Type 2 Diabetes Mellitus, Postmenopausal Osteoporosis, Alzheimer's Disease. NovaPharmaNews links 8 clinical program(s), 0 drug profi

• Is Dong Wang publicly traded?

  Dong Wang appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Dong Wang develop or market?

  We link 13 drug profile(s) where Dong Wang is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dong-wang#company-drugs.

• What are the latest developments for Dong Wang?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dong Wang focus on?

  Dong Wang focuses on Androgenetic Alopecia, Acute Myocardial Infarction, Type 2 Diabetes Mellitus based on our analysis of their pipeline programs and drug development activities.